Barrick stock rises after report of Newmont eyeing Nevada gold assets
Investing.com -- STRATA Skin Sciences Inc (NASDAQ:SSKN) stock surged 40% on Tuesday following the publication of a peer-reviewed study demonstrating superior efficacy of its 308nm Excimer laser when combined with JAK inhibitors for vitiligo treatment.
The 251-patient randomized controlled trial, published in the International Journal of Dermatology, showed the combination therapy achieved 14.20% higher repigmentation rates compared to monotherapy, with a 100% significant efficacy rate after 52 weeks of treatment. The study also reported high pigmentation stability (96.5%) and a low relapse rate (8.8%) at one-year follow-up.
"This investigator-initiated study, which features a much larger patient population than normally seen in contemporary dermatology studies, highlights the continued interest in our Excimer laser technology, and the promise of combination therapy," said STRATA CEO Dr. Dolev Rafaeli.
The company noted that the study supports its current pursuit of expanded reimbursement for various indications, including vitiligo and psoriasis, which it hopes to secure by early 2026. STRATA’s Excimer technology has been in use for approximately 20 years and has been featured in over 400 studies and peer-reviewed papers.
The research demonstrated a mechanistic synergy between the two treatments, with JAK inhibitors suppressing immune responses while the Excimer laser promotes melanocyte migration. Importantly, the study reported no serious or persistent adverse events, confirming the safety profile of the combination approach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.